Moexipril Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Feb 27, 2023.
Moexipril is also known as: Univasc
Moexipril Pregnancy Warnings
Animal studies have failed to reveal evidence of embryo or fetal toxicity or teratogenicity. In humans, use of drugs that act on the renin angiotensin system (RAS) during the second and third trimesters increases fetal and neonatal morbidity and death. There are no controlled data in human pregnancy.
US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
UK: Use is not recommended during the first trimester of pregnancy and is contraindicated during the second and third trimesters.
US: This drug should not be used during pregnancy unless there are no alternatives and the benefit outweighs the risk to the fetus.
US FDA pregnancy category: D
Comments: Adequate methods of contraception should be encouraged.
Moexipril Breastfeeding Warnings
UK: Use is not recommended.
US: Caution is recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- "Product Information. Univasc (moexipril)." Schwarz Pharma (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
References for breastfeeding information
- "Product Information. Univasc (moexipril)." Schwarz Pharma (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
